DataMeds AI, Inc.
MEDS evidence brief
What we can confirm
- Market Cap:
- $2.8M
What it means
What to watch
Prepared research question
What matters most for MEDS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MEDS
DataMeds AI, Inc. (MEDS) is a healthcare technology company that combines a Health IT platform, artificial intelligence, and a pharmacy division to offer telehealth, prescription fulfillment, and diagnostic services.
Key risk: Negative equity and high debt
Market Cap
$2.8M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
DataMeds AI, Inc. (MEDS) is a healthcare technology company that combines a Health IT platform, artificial intelligence, and a pharmacy division to offer telehealth, prescription fulfillment, and diagnostic services.
- Cash & equivalents of $2.5M as of 2026-06-30 [sec].
- Total revenue of $1.8M and net loss of -$18.4M for the period ended 2026-06-30 [sec].
- Shareholders' equity of -$19.5M and total debt of $40.6M as of 2026-06-30 [sec].
- Corexa Pharmacy generated preliminary September 2026 revenue of more than $1 million, up 66% from July 2026 [news · 2026-10-01].
- Completed acquisition of Helomics for $1.5M in September 2026, adding a certified oncology laboratory and contract research services [news · 2026-09-16].
What works
- Corexa Pharmacy's monthly revenue surpassed $1 million in September 2026, showing strong growth from $600K+ in July 2026 [news · 2026-10-01].
- The company expanded its product portfolio with GLP-1 agonist drugs, medical foods, and dietary supplements, and integrated its online store into the Health Lives Here app [news · 2026-08-12].
- The acquisition of Helomics adds a certified oncology laboratory and contract research services, expanding into cancer diagnostics [news · 2026-09-16].
What to weigh
- As of 2026-06-30, the company had a net loss of -$18.4M and negative shareholders' equity of -$19.5M, indicating significant financial losses [sec].
- Total debt of $40.6M as of 2026-06-30 far exceeds cash & equivalents of $2.5M, raising concerns about solvency [sec].
- The company changed its name from Wellgistics Health, Inc. to DataMeds AI, Inc. in July 2026, which may create brand confusion or signal strategic shifts [news · 2026-08-17].
From the filings
Quoted directly from source documents.
Corexa Pharmacy September 2026 revenue exceeded $1 million
“Corexa Pharmacy generated preliminary, unaudited September 2026 revenue of more than $1 million”
News · October 1, 2026
Acquisition of Helomics for $1.5M
“DataMEDS AI Completes $1.5 Million Helomics Acquisition, Expanding into Cancer Diagnostics”
News · September 16, 2026
Corporate name change from Wellgistics Health to DataMeds AI
“Corporate name change from Wellgistics Health, Inc. to DataMeds AI, Inc. in July 2026”
News · August 17, 2026
Risks & what to watch (3)›
Key risks
- Negative equity and high debt — Shareholders' equity of -$19.5M and total debt of $40.6M as of 2026-06-30 indicate severe financial imbalance [sec].
- Net loss continues — Net loss of -$18.4M for the period ended 2026-06-30 shows ongoing profitability challenges [sec].
- Cash runway limited — Cash & equivalents of $2.5M as of 2026-06-30 may be insufficient to cover operating losses and debt service [sec].
What to watch
- Monitor whether Corexa Pharmacy's monthly revenue growth continues and if it can achieve sustained profitability [news · 2026-10-01].
- Track integration and revenue contribution from the Helomics acquisition in cancer diagnostics [news · 2026-09-16].
- Watch for updates on the Health Lives Here app adoption and its impact on GLP-1 telehealth and pharmacy services [news · 2026-09-28].
- Observe any further financial disclosures or capital raises to address the negative equity and high debt levels [sec].
Sources: News · Generated October 5, 2026 · How we verify sources →
Run DataMeds AI, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available DataMeds AI, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
13
Total value held
$205K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 710,766 | $69K |
| vanguard capital management llc | 604,226 | $58K |
| vanguard fiduciary trust co | 309,584 | $30K |
| state street corp | 124,600 | $12K |
| jane street group, llc | 93,980 | $9K |
| northern trust corp | 74,063 | $7K |
| raymond james financial inc | 58,421 | $6K |
| act advisors, llc. | 35,389 | $3K |
| xtx topco ltd | 31,501 | $3K |
| point72 asset management, l.p. | 27,324 | $3K |
Showing top 10 of 13 institutional holders of DataMeds AI, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 3.6%
- Days to cover
- 0.1
- Shares short
- 2,676,448
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MEDS short interestFrequently asked questions
What is the AI investment thesis for DataMeds AI, Inc.?
DataMeds AI, Inc. (MEDS) is a healthcare technology company that combines a Health IT platform, artificial intelligence, and a pharmacy division to offer telehealth, prescription fulfillment, and diagnostic services.
Who is the CEO of DataMeds AI, Inc.?
Mr. Prashant Patel M.Sc., R.Ph. is the chief executive officer of DataMeds AI, Inc. (MEDS).
Where is DataMeds AI, Inc. headquartered?
DataMeds AI, Inc. (MEDS) is headquartered in Tampa, FL, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.